Quarterly ResultMay 14, 2026, 04:24 PM
MariMed Q1 Revenue +4.2% to $39.5M; Net Loss Narrows to $3.8M
AI Summary
MariMed Inc. reported a 4.2% increase in revenue to $39.5 million for the first quarter of 2026, while significantly narrowing its net loss to $3.8 million from $5.5 million in the prior year. The company achieved positive income from operations of $0.1 million, a notable improvement from a loss in the previous year, partly due to a substantial reduction in bad debt expense. However, net cash provided by operating activities decreased, and total liabilities increased during the quarter, alongside a restructuring of preferred stock into new preferred stock and notes payable.
Key Highlights
- Revenue increased 4.2% to $39.5 million for Q1 2026, up from $37.9 million in Q1 2025.
- Net loss attributable to common stockholders narrowed to $3.8 million, an improvement from $5.5 million in Q1 2025.
- Income from operations was $0.1 million in Q1 2026, compared to a loss of $0.9 million in Q1 2025.
- Bad debt expense significantly decreased to $0.1 million in Q1 2026 from $1.4 million in Q1 2025.
- The company exchanged Series B preferred stock for new Series B preferred stock ($6.9 million) and notes payable ($7.1 million).
- Net cash provided by operating activities decreased to $0.9 million in Q1 2026 from $1.3 million in Q1 2025.
- Total liabilities increased to $147.7 million at March 31, 2026, from $137.8 million at December 31, 2025.
Price Impact
More from MRMD